We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Allergan plc will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.
Allergan’s share price was up 9.1% this year so far, while the Zacks classified Medical-Generics Drug industry witnessed a 2.1% decline.
Allergan’s earnings performance has been mixed so far, with the company beating expectations in three of the past four quarters and missing on one occasion. The average negative earnings surprise over the last four quarters is 0.50%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
We believe that Allergan’s revenues will be driven by product launches, international growth and performance of key established products like Botox, Linzess and Restasis. On the other hand, earnings growth will be driven by the top line, operating expense management and a lower share count.
Performance of new products like Avycaz (complicated intra-abdominal and urinary tract infections in adult patients), Vraylar (bipolar I disorder and schizophrenia), Kybella (double chin) and Viberzi (irritable bowel syndrome with diarrhea in adults) will be in focus. Viberzi, Dalvance and Vraylar did well in the third quarter and we expect the trend to continue in the fourth quarter.
However, Namenda IR is facing generic competition which will continue to hurt its sales. Investors should also be interested in Namzaric’s performance. Namzaric is a once-daily, fixed-dose combination of Namenda XR and Aricept. Meanwhile, Asacol/Delzicol sales will continue being hurt by sluggish demand for Ascaol HD following the launch of an authorized generic in Aug 2016.
On the flip side, Allergan has made many acquisitions in the past few months including Tobira Therapeutics, RetroSense Therapeutics, Chase Pharma, ForSight VISION5 and Vitae Pharmaceuticals. These acquisitions should add to its top line in the fourth quarter.
Allergan sold its generics and Anda distribution business to Teva Pharmaceutical Industries Limited (TEVA - Free Report) in Aug and Oct 2016, respectively. Both these business lines will be treated as discontinued operations.
Meanwhile, higher costs will continue to put pressure on profits.
Earnings Whispers
Our proven model does not conclusively show that Allergan is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Most Accurate estimate stands at $3.75, while the Zacks Consensus Estimate is pegged higher at $3.76. This results in an Earnings ESP of -0.27%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Allergan’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Some stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are:
Kite Pharma, Inc. has an Earnings ESP of +13.64% and a Zacks Rank #3. The company is expected to release results next month.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
Allergan plc will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.
Allergan’s share price was up 9.1% this year so far, while the Zacks classified Medical-Generics Drug industry witnessed a 2.1% decline.
Allergan’s earnings performance has been mixed so far, with the company beating expectations in three of the past four quarters and missing on one occasion. The average negative earnings surprise over the last four quarters is 0.50%.
Allergan PLC. Price and EPS Surprise
Allergan PLC. Price and EPS Surprise | Allergan PLC. Quote
Let’s see how things are shaping up for this announcement.
Factors to Consider
We believe that Allergan’s revenues will be driven by product launches, international growth and performance of key established products like Botox, Linzess and Restasis. On the other hand, earnings growth will be driven by the top line, operating expense management and a lower share count.
Performance of new products like Avycaz (complicated intra-abdominal and urinary tract infections in adult patients), Vraylar (bipolar I disorder and schizophrenia), Kybella (double chin) and Viberzi (irritable bowel syndrome with diarrhea in adults) will be in focus. Viberzi, Dalvance and Vraylar did well in the third quarter and we expect the trend to continue in the fourth quarter.
However, Namenda IR is facing generic competition which will continue to hurt its sales. Investors should also be interested in Namzaric’s performance. Namzaric is a once-daily, fixed-dose combination of Namenda XR and Aricept. Meanwhile, Asacol/Delzicol sales will continue being hurt by sluggish demand for Ascaol HD following the launch of an authorized generic in Aug 2016.
On the flip side, Allergan has made many acquisitions in the past few months including Tobira Therapeutics, RetroSense Therapeutics, Chase Pharma, ForSight VISION5 and Vitae Pharmaceuticals. These acquisitions should add to its top line in the fourth quarter.
Allergan sold its generics and Anda distribution business to Teva Pharmaceutical Industries Limited (TEVA - Free Report) in Aug and Oct 2016, respectively. Both these business lines will be treated as discontinued operations.
Meanwhile, higher costs will continue to put pressure on profits.
Earnings Whispers
Our proven model does not conclusively show that Allergan is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Most Accurate estimate stands at $3.75, while the Zacks Consensus Estimate is pegged higher at $3.76. This results in an Earnings ESP of -0.27%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Allergan’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Some stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are:
Acorda Therapeutics, Inc. is expected to release results on Feb 14. The company has an Earnings ESP of 5.56% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Kite Pharma, Inc. has an Earnings ESP of +13.64% and a Zacks Rank #3. The company is expected to release results next month.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>